These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 25464435)

  • 1. Absolute change in fasting plasma glucose over 12 months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants.
    Kang DO; Seo HS; Choi BG; Lee E; Kim JP; Lee SK; Im SI; Na JO; Choi CU; Lim HE; Kim JW; Kim EJ; Rha SW; Park CG; Oh DJ
    Int J Cardiol; 2015 Jan; 179():146-52. PubMed ID: 25464435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of patients of over 85 years old with acute coronary syndrome undergoing percutaneous coronary stenting: a comparison of bare metal stent and drug eluting stent.
    Ma HY; Zhou YJ; Dick RJ; Shi DM; Liu YY; Cheng WJ; Guo YH; Wang JL; Ge HL
    Chin Med J (Engl); 2008 May; 121(10):887-91. PubMed ID: 18706201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.
    Novack V; Tsyvine D; Cohen DJ; Pencina M; Dubin J; Dehghani H; Kleiman NS; Cutlip DE
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):874-80. PubMed ID: 19180665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions.
    Han YL; Zhang J; Li Y; Wang SL; Jing QM; Yi XH; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2009 Mar; 122(6):643-7. PubMed ID: 19323927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct drug-eluting stenting to reduce stent restenosis: a randomized comparison of direct stent implantation to conventional stenting with pre-dilation or provisional stenting in elective PCI patients.
    Remkes WS; Somi S; Roolvink V; Rasoul S; Ottervanger JP; Gosselink AT; Hoorntje JC; Dambrink JH; de Boer MJ; Suryapranata H; van 't Hof AW;
    JACC Cardiovasc Interv; 2014 Jul; 7(7):751-8. PubMed ID: 25060017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial.
    Tuomainen PO; Ylitalo A; Niemelä M; Kervinen K; Pietilä M; Sia J; Nyman K; Nammas W; Airaksinen KE; Karjalainen PP
    Int J Cardiol; 2013 Sep; 168(2):1214-9. PubMed ID: 23218575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
    Chen SL; Sheiban I; Xu B; Jepson N; Paiboon C; Zhang JJ; Ye F; Sansoto T; Kwan TW; Lee M; Han YL; Lv SZ; Wen SY; Zhang Q; Wang HC; Jiang TM; Wang Y; Chen LL; Tian NL; Cao F; Qiu CG; Zhang YJ; Leon MB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1266-76. PubMed ID: 25326748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of drug-eluting stent implantation for patients with multiple coronary chronic total occlusions.
    Zhang J; Han YL; Li Y; Wang SL; Jing QM; Wang XZ; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2010 Apr; 123(7):789-93. PubMed ID: 20497665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcomes between first-generation and second-generation drug-eluting stents in type 2 diabetic patients.
    Jeong HS; Cho JY; Kim EJ; Yu CW; Ahn CM; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2013 Dec; 24(8):676-83. PubMed ID: 23994881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
    Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.